AI-designed universal Sarbeco coronavirus vaccine completes first human safety trial (cam.ac.uk)

• 39 healthy volunteers received AI-designed universal Sarbeco coronavirus vaccine
• Vaccine safe, no significant side-effects, broad immune response
• AI super-antigen targets multiple coronaviruses including bat viruses
• Phase 2 trial to follow

"A phase 1 clinical trial of a universal Sarbeco coronavirus vaccine developed by University of Cambridge and DIOSynVax showed safety and broad immune responses in 39 volunteers. The vaccine uses an AI-designed super-antigen to target multiple coronaviruses, including bat viruses. It was administered via needle-free injection. Results published in Journal of Infection."